Newswise — HACKENSACK, NJ – May 24, 2021 – Hackensack Meridian Health, New Jersey’s largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a research collaboration agreement that initially aims to help address the significant unmet needs of people living with Alzheimer’s disease, especially those experiencing the earliest stages of the disease, known as Mild Cognitive Impairment.
“We are proud to join forces with Eisai in our quest to expand early Alzheimer’s disease detection and improve community services for patients, caregivers and families impacted by the disease and other types of dementia,” said Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. “Hackensack Meridian Health’s mission is to transform health care and this collaboration will help us to…
